Lite Strategy, Inc.
NCM: LITSLive Quote
About Lite Strategy, Inc.
Healthcare
Biotechnology
Lite Strategy, Inc. a clinical-stage pharmaceutical company, focuses on the development of novel and differentiated therapies for the treatment of cancer. The company was formerly known as MEI Pharma, Inc. and changed its name to Lite Strategy, Inc. in September 2025. Lite Strategy, Inc. was incorporated in 2000 and is based in San Diego, California.
📊 Fundamental Analysis
Lite Strategy, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -76.4%, which indicates that capital utilization is currently under pressure.
At a current price of $1.16, LITS currently trades near the bottom of its 52-week range (3%), indicating potential value or weakness (Range: $0.95 - $9.00).
🏥 Financial Health
🔴
Profit Margin
Weak
🔴
Return on Equity
Weak
✅
Beta (Risk)
Low Volatility
Key Financials
Market Cap
$25.73M
Trailing P/E
--
Forward P/E
--
Beta (5Y)
0.10
52W High
$9.00
52W Low
$0.95
Avg Volume
352K
Day High
Day Low
📡 Subscribe to ZcoreAI updates
Join the list to get access to:
- Z-Score signals at market open
- New app features and updates
- Exclusive promo for ZcoreAI App